An NR3C1 diallelic single nucleotide polymorphism, Bcl-1, has been reported to distinguish individuals with the highest GC sensitivity.(6) The aim of the present study was to investigate the association between the NR3C1 gen (Bcl-1-CG) polymorphism and the response to therapy among RA patients and healthy control subjects.
The distribution of the NR3C1 Bcl-1 polymorphism in the intron 2 polymorphism were evaluated in RA patients and healthy control populations by using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
Digestion of PCR product by the Bcl-1 enzyme generated one fragment for homozygous G/G, three fragments for heterozygote G/C, and two fragments for homozygous C/C (Figure 1).
Genotype frequencies of the NR3C1 Bcl-1 polymorphism did not differ between the patients with RA and the controls (table 2).
Frequency of Bcl-1 genotypes in control and rheumatoid arthritis cases NR3C1 gene Rheumatoid arthritis Healthy OR (n=65) control (n=70) n % n % BCL-1 polymorphism Genotype CC 35 53.8 42 60 3.023* CG 20 30.8 24 34.3 2.933* GG 10 15.4 4 5.7 3.000[dagger] NR3C1 gene 95% CI p BCL-1 polymorphism Genotype CC 0.870-10.506* 0.082* CG 0.795-10.821* 0.106* GG 0.891-10.096[dagger] 0.090[dagger] # High expression; t Low expression; * OR (95%CI) was adjusted by age and sex; t Fisher's Exact Test.
For oral administration, BCL-1, 400 mg/kg; BCL-2, 800 mg/kg; BCL-3, 1600 mg/kg; BCL-4, 3200 mg/kg; BCL-5, 6400 mg/kg.
BCL-1, -2 and -3 were test groups treated with BCL (400, 800 and 1600 mg/kg respectively, p.o.).
We present the lymph node morphology, the incidence and patterns of bone marrow involvement, and the results of available cyclin D1 immunostaining and bcl-1 gene rearrangement analyses in 19 cases of large cell variants of [CD5.sup.+], [CD23.sup.-] BCL/B-cell leukemia.
DNA was extracted from nodal or extranodal tissue and bone marrow aspirate as described previously. Polymerase chain reaction analysis of the translocation involving the major translocation cluster of the bcl-1 gene and the immunoglobulin heavy-chain gene was performed using both primer pairs, mcl-1/[J.sub.h] and mcl-2/[J.sub.h], as previously described.
Bcl-1 analysis was performed in a total of 5 cases (4 blastic [CD5.sup.+], [CD23.sup.-] BCLs and 1 MCL-P).
Mantle cell lymphoma and its leukemic phase constitute a well-studied hematologic malignancy with known overall survival, prognostic indicators, morphologic findings at diagnosis and in bone marrow, and known incidence of bcl-1 immunoglobulin gene rearrangements.
However, the immunophenotypic features and presence of a bcl-1 gene rearrangement supported the mantle cell origin.